Trends in Pharmacological Sciences
ReviewSpecial issue: Pharmacology in The NetherlandsPreservation of β-cell function by targeting β-cell mass
Introduction
Although there are several subtypes of diabetes mellitus, each with a different pathogenesis, it is now recognized that a defect in insulin secretion caused by a deficit and/or functional impairment in insulin-producing β cells in the pancreatic islets of Langerhans has a key role in the development of hyperglycemia (Figure 1, Figure 2). The time of onset, the speed of progression and the nature of precipitating external and genetic factors that cause the defect in insulin secretion vary in the different subtypes.
Type 2 diabetes is by far the most common subtype, and its occurrence is increasing rapidly because of an imbalance between food intake and energy expenditure, which leads to obesity and insulin resistance [1]. A combination of genetic factors and the adverse metabolic milieu causes a gradual deterioration in β-cell function until hyperglycemia develops in susceptible individuals: for instance, those with abdominal obesity or a history of gestational diabetes mellitus [2]. Once hyperglycemia has developed, oral anti-hyperglycemic drugs are prescribed to improve glycemic control. But this strategy clearly fails to halt the progressive insulin secretion defect in type 2 diabetes, as reflected by the eventual need for additional oral anti-hyperglycemic medication and conversion to insulin treatment in a large number of patients.
In this article, we address the mechanisms involved in β-cell dysfunction and β-cell loss to provide a rationale for why preservation and/or expansion of a functional β-cell mass is a logical approach for pharmacological intervention in type 2 diabetes.
Section snippets
β-Cell mass in normal physiology and in type 2 diabetes
β-Cell mass is determined and maintained by the balance of islet neogenesis (formation of islets from islet precursor cells), hyperplasia (replication of pre-existing β cells), hypertrophy (increase in size of individual β cells) and apoptosis (programmed cell death) [3]. During growth and development, islet neogenesis and β-cell replication are key mechanisms in β-cell mass expansion.
Changes in insulin sensitivity induce changes in insulin secretion to keep glucose concentrations within a
Mechanisms of β-cell dysfunction that can be targeted by pharmacological intervention
The concept that pancreatic islets are a target for adverse effectors associated with adiposity and insulin resistance, which result in islet (target organ) damage, indicates that pharmacological intervention strategies could be aimed at counteracting these factors or protecting the target β cells (Figure 3). Monitoring such a strategy is not easy because β-cell mass cannot be visualized and there are no circulating biomarkers for it. In clinical practice, a crude proxy for preservation of
Anti-hyperglycemic agents
Many observations indicate a detrimental effect (via several biochemical pathways) of high concentrations of glucose on glucose sensing, insulin gene expression, insulin secretion and β-cell survival once overt diabetes has developed (reviewed in Refs 20, 21) (Figure 3, Figure 4). This adverse effect, termed glucotoxicity, has relevant therapeutic consequences, implying that every glucose-lowering strategy aimed at achieving normoglycemia would improve β-cell function and glucose homeostasis.
GLP-1 and GLP-1 receptor agonists
It has long been recognized that there is greater insulin secretion in response to an oral glucose load than to an intravenous glucose load, even when the glucose concentrations after both challenges are similar. This observation has been termed the ’incretin’ effect and is due to the release of incretin hormones from gastrointestinal neuroendocrine cells. The two main incretin hormones are glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP) (reviewed in Refs 52
Future pharmacological targets: expansion of β-cell mass
The in vivo expansion of β-cell mass is an attractive new area of pharmacological intervention [99]. Identifying and understanding the mechanisms of effectors that are crucial in islet neogenesis and β-cell proliferation, not only during growth and development but also during adaptation of the β-cell mass in a changing metabolic environment in adulthood, are essential. Several factors that stimulate β-cell growth in rodents have been identified and could offer a similar expansion in humans.
One
References (117)
Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet β-cells in diabetes
J. Biol. Chem.
(2004)Critical reduction in β-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes
J. Biol. Chem.
(2003)Role of VEGF-A in vascularization of pancreatic islets
Curr. Biol.
(2003)Changes in islet capillary angioarchitecture coincide with impaired β-cell function but not with insulin resistance in male Otsuka-Long-Evans-Tokushima fatty rats: dimorphism of the diabetic phenotype at an advanced age
Metabolism
(1999)- et al.
The pancreatic islet endothelial cell: emerging roles in islet function and disease
Int. J. Biochem. Cell Biol.
(2006) Peritubular endothelium: the Achilles heel of the kidney?
Kidney Int.
(2007)- et al.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Lancet
(2006) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
Lancet
(2002)Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
Regul. Pept.
(2003)The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
Biochem. Biophys. Res. Commun.
(2005)
Glucagon-like peptide-1 receptor signaling modulates β-cell apoptosis
J. Biol. Chem.
cAMP dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP–guanine nucleotide exchange factor-dependent pathways in β-cells
J. Biol. Chem.
Enhanced secretion of glucagon-like peptide 1 by biguanide compounds
Biochem. Biophys. Res. Commun.
Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: possible protection of β-cells from oxidative stress
Metabolism
Protection of human islets from the effects of interleukin-1β by adenoviral gene transfer of an IκB repressor
J. Biol. Chem.
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030
Diabetes Care
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Nature
Perspective: postnatal pancreatic β-cell growth
Endocrinology
Glucokinase and IRS-2 are required for compensatory β-cell hyperplasia in response to high-fat diet-induced insulin resistance
J. Clin. Invest.
A dominant role for glucose in β-cell compensation of insulin resistance
J. Clin. Invest.
β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes
Diabetes
Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited
Surv. Synth. Pathol. Res.
Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey
Diabetologia
Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in β-cell population
Diabetologia
Reduced β-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients
Diabetologia
Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea
J. Clin. Endocrinol. Metab.
Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat
Diabetes
Dual role of proapoptotic BAD in insulin secretion and β-cell survival
Nat. Med.
Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans
N. Engl. J. Med.
Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy
J. Clin. Invest.
Dynamics of β-cell mass in the growing rat pancreas. Estimation with a simple mathematical model
Diabetes
Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy
Diabetes
Decrease in β-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig
Diabetes
Decreased insulin- and glucagon-pulse amplitude accompanying β-cell deficiency induced by streptozocin in baboons
Diabetes
β-Cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion
Diabetes Care
NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X
Diabetologia
Inflammation and insulin resistance
J. Clin. Invest.
Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes
J. Mol. Med.
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
Circulation
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance
Diabetes
Glucose-induced β-cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
J. Clin. Invest.
Leptin modulates β-cell expression of IL-1 receptor antagonist and release of IL-1β in human islets
Proc. Natl. Acad. Sci. U. S. A.
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
N. Engl. J. Med.
Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets
Diabetologia
Vascular reactivity in arterioles from normal and alloxan-diabetic mice: studies on single perfused islets
Diabetes
Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts
Diabetologia
Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes
J. Hypertens.
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity
Circulation
Improved islet morphology after blockade of the renin–angiotensin system in the ZDF rat
Diabetes
Induction of pancreatic differentiation by signals from blood vessels
Science
Cited by (60)
Combined therapy of GABA and sitagliptin prevents high-fat diet impairment of beta-cell function
2023, Molecular and Cellular EndocrinologyCitation Excerpt :β-cell mass may increase due to β-cell proliferation, β-cell hypertrophy, or transdifferentiation from other cell types (Kushner et al., 2010). However, proliferation of mature β cells is considered to be the dominant mechanism in adult rodents and humans (de Koning et al., 2008; Kushner et al., 2010; Georgia and Bhushan, 2004). We have shown that combination therapy of γ-aminobutyric acid (GABA) and the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (that raises GLP-1 plasma levels), could promote β-cell proliferation in the streptozotocin (STZ)-induced β-cell injury mouse model (Liu et al., 2017).
Friedelin exhibits antidiabetic effect in diabetic rats via modulation of glucose metabolism in liver and muscle
2021, Journal of EthnopharmacologyIntermittent fasting benefits on alpha- and beta-cell arrangement in diet-induced obese mice pancreatic islet
2020, Journal of Diabetes and its ComplicationsHepatic transcriptome and proteome analyses provide new insights into the regulator mechanism of dietary avicularin in diabetic mice
2019, Food Research InternationalEffect of CAPE-pNO<inf>2</inf> against type 2 diabetes mellitus via the AMPK/GLUT4/ GSK3β/PPARα pathway in HFD/STZ-induced diabetic mice
2019, European Journal of PharmacologyCitation Excerpt :The effect of CAPE-pNO2 on PPARα was slightly better than that of CAPE, but their difference was not statistically significant. Type 2 diabetes mellitus, one of the most common metabolic disorders, is characterized by relative deficiency of insulin secretion and insulin resistance in peripheral tissues (Martin et al., 1992; de Koning et al., 2008). Both insulin secretory dysfunction and insulin resistance have effect on every stage of T2DM, and clinical prevention and treatment of T2DM mainly starts from reducing insulin resistance and insulin secretory dysfunction (Pratley and Weyer, 2001).
BH3 mimetics derived from Bim-BH3 domain core region show PTP1B inhibitory activity
2019, Bioorganic and Medicinal Chemistry Letters